Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astellas Pharma Inc (ALPMF)
OTHER OTC:ALPMF
Holding ALPMF?
Track your performance easily
ALPMF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.96 - $14.88
Previous Close$12.1
Volume2.00K
Average Volume (3M)3.29K
Market Cap
$21.42B
Enterprise Value$18.96B
Total Cash (Recent Filing)¥413.30B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)205.4
Beta0.28
Next Earnings
Oct 31, 2024EPS Estimate
$0.11Next Dividend Ex-Date
Sep 27, 2024Dividend Yield4.01%
Share Statistics
EPS (TTM)0.06
Shares OutstandingN/A
10 Day Avg. Volume6,314
30 Day Avg. Volume3,285
Standard Deviation0.07
R-Squared0.00684
Alpha0.00181
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)2.48
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$13.06Price Target Upside12.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Astellas Pharma News
PremiumCompany Announcements
Astellas Pharma Prices New Unsecured Bonds
PremiumCompany Announcements
Astellas Gains EC Approval for Advanced Urothelial Cancer Treatment
PremiumCompany Announcements
New Urothelial Cancer Treatment Approved in China
PremiumCompany Announcements
Astellas Pharma Records ¥5.5 Billion Charge
PremiumCompany Announcements
Astellas Nears EU Approval for Groundbreaking Cancer Drug
PremiumCompany Announcements
Astellas’ New Therapy Set to Transform Bladder Cancer TreatmentOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
6.02% Mutual Funds
9.35% Other Institutional Investors
84.63% Public Companies and
Individual Investors
ALPMF FAQ
What was Astellas Pharma Inc’s price range in the past 12 months?
Astellas Pharma Inc lowest stock price was $8.96 and its highest was $14.88 in the past 12 months.
What is Astellas Pharma Inc’s market cap?
Currently, no data Available
When is Astellas Pharma Inc’s upcoming earnings report date?
Astellas Pharma Inc’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Astellas Pharma Inc’s earnings last quarter?
Astellas Pharma Inc released its earnings results on Aug 01, 2024. The company reported $0.149 earnings per share for the quarter, beating the consensus estimate of $0.068 by $0.081.
Is Astellas Pharma Inc overvalued?
According to Wall Street analysts Astellas Pharma Inc’s price is currently Undervalued.
Does Astellas Pharma Inc pay dividends?
Astellas Pharma Inc pays a Annually dividend of $0.26 which represents an annual dividend yield of 4.01%. See more information on Astellas Pharma Inc dividends here
What is Astellas Pharma Inc’s EPS estimate?
Astellas Pharma Inc’s EPS estimate is $0.11.
How many shares outstanding does Astellas Pharma Inc have?
Astellas Pharma Inc has 1,809,663,100 shares outstanding.
What happened to Astellas Pharma Inc’s price movement after its last earnings report?
Astellas Pharma Inc reported an EPS of $0.149 in its last earnings report, beating expectations of $0.068. Following the earnings report the stock price went down -1.724%.
Which hedge fund is a major shareholder of Astellas Pharma Inc?
Currently, no hedge funds are holding shares in ALPMF
---
Astellas Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.06 (12.01% Upside)
$13.06 (12.01% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.94%
12-Months-Change
Fundamentals
Return on Equity
0.99%
Trailing 12-Months
Asset Growth
19.96%
Trailing 12-Months
Company Description
Astellas Pharma Inc
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
---
ALPMF Company Deck
---
ALPMF Earnings Call
Q1 2024
0:00 / 0:00
---
ALPMF Stock 12 Month Forecast
Average Price Target
$13.06
▲(12.01% Upside)
Technical Analysis
Best Analysts Covering ALPMF
1 Year
---